Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Psychiatry Reports
Erschienen in: Current Psychiatry Reports 4/2012

01.08.2012 | Geriatric Disorders (Dc Steffens, Section Editor)

Mild Cognitive Impairment in Older Adults

verfasst von: Yonas E. Geda

Erschienen in: Current Psychiatry Reports | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Mild cognitive impairment (MCI) is the intermediate stage between the cognitive changes of normal aging and dementia. MCI is important because it constitutes a high risk group for dementia. Ideally, prevention strategies should target individuals who are not even symptomatic. Indeed, the field is now moving towards identification of asymptomatic individuals who have underlying Alzheimer’s disease (AD) pathology that can be detected using biomarkers and neuroimaging technologies. To this effect, the Alzheimer’s Association and the National Institute on Aging have developed a new classification scheme that has categorized AD into a preclinical phase (research category), MCI due to AD, and dementia of Alzheimer’s type. However, there are also ongoing research studies to understand high-risk groups for non-Alzheimer’s dementia.
Literatur
1.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8.PubMedCrossRef
2.
Reisberg B, Ferris SH, de Leon MJ, Crook T. Global Deterioration Scale (GDS). Psychopharmacol Bull. 1988;24:661–3.PubMed
3.
Reisberg B, Ferris SH, de Leon MJ, et al. Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer's type. Drug Development Research. 1988;15:101–114.
4.
Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991;41:1006–9.PubMedCrossRef
5.
Kral VA. Senescent forgetfulness: benign and malignant. Can Med Assoc J. 1962;86:257–60.PubMed
6.
Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon S. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change—report of a National Institute of Mental Health work group. Development Neuropsychol. 1986;2:261–76.CrossRef
7.
Levy R. Aging-associated cognitive decline. Working party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr. 1994;6:63–8.PubMedCrossRef
8.
American Psychiatric Association, American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.
9.
Blackford RC, La Rue A. Criteria for diagnosing age-associated memory impairment: proposed improvements from the field. Development Neuropsychol. 1989;5:295–306.CrossRef
10.
Devanand DP, Folz M, Gorlyn M, Moeller JR, Stern Y. Questionable dementia: clinical course and predictors of outcome. J Am Geriatr Soc. 1997;45:321–8.PubMed
11.
Reisberg B, Prichep L, Mosconi L, John ER, Glodzik-Sobanska L, Boksay I, et al. The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease. Alzheimers Dement. 2008;4 Suppl 1:S98–108.PubMedCrossRef
12.
Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59–66.PubMedCrossRef
13.
•• Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011;364:2227–34. This reference is the most up-to-date review, particularly on advances made in the area of biomarkers and neuroimaging research pertinent to MCI and AD.PubMedCrossRef
14.
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240–6.PubMedCrossRef
15.
Williams JW, United States. Agency for Healthcare Research and Quality. Duke University Evidence-based Practice Center. Preventing Alzheimer's disease and cognitive decline. Evidence report/technology assessment,, vol no 193. Agency for Healthcare Research and Quality, Rockville, MD; 2010.
16.
Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337–42.PubMedCrossRef
17.
Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3:186–91.PubMedCrossRef
18.
Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, et al. The economic burden of Alzheimer's disease care. Health Aff (Millwood). 1993;12:164–76.CrossRef
19.
Geda YE, Negash S, Petersen RC. Memory disorders. In: Agronin ME, Maletta GJ (eds). Principles and practice of geriatric psychiatry. Lippincott Williams & Wilkins, Philadelphia, PA; 2006.
20.
Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–92.PubMedCrossRef
21.
• Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280–92. This article describes AA-NIA research criteria for asymptomatic AD. Very useful in a research setting.PubMedCrossRef
22.
• Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270–9. This article describes the criteria for MCI due to AD.PubMedCrossRef
23.
• McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–9. This article describes the AA-NIA criteria for the diagnosis of dementia due to AD. Involvement of memory domain does not have a central place in the diagnostic criteria for dementia of Alzheimer's type. This is in sharp contrast with the DSM-IV criteria for dementia of Alzheimer's type.PubMedCrossRef
24.
•• Ganguli M, Blacker D, Blazer DG, Grant I, Jeste DV, Paulsen JS, et al. Classification of neurocognitive disorders in DSM-5: a work in progress. Am J Geriatr Psychiatry. 2011;19:205–10. This is a very important reference in order to understand the ongoing work of the DSM-5 task force on neurocognitive disorders, including MCI.PubMedCrossRef
25.
Molano J, Boeve B, Ferman T, Smith G, Parisi J, Dickson D, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain. 2010;133:540–56.PubMedCrossRef
26.
Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology. 2004;63:115–21.PubMedCrossRef
27.
Hanninen T, Hallikainen M, Tuomainen S, Vanhanen M, Soininen H. Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta Neurol Scand. 2002;106:148–54.PubMedCrossRef
28.
Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59:1594–9.PubMedCrossRef
29.
•• Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, et al. The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic study of aging. Neurology. 2012;78:342–51. This reference contains the most recent population-based estimates of the incidence of MCI. Thearticle has reported unexpected differences in incidence of MCI by sex, i.e., the incidence of MCI is higher in men than in women.PubMedCrossRef
30.
31.
Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic study of aging. Neurology. 2010;75:889–97.PubMedCrossRef
32.
Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, et al. The Mayo Clinic study of aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30:58–69.PubMedCrossRef
33.
Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular health study cognition study: part 1. Arch Neurol. 2003;60:1385–9.PubMedCrossRef
34.
Kumar R, Dear KB, Christensen H, Ilschner S, Jorm AF, Meslin C, et al. Prevalence of mild cognitive impairment in 60- to 64-year-old community-dwelling individuals: the personality and total health through Life 60+ Study. Dement Geriatr Cogn Disord. 2005;19:67–74.PubMedCrossRef
35.
Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–88.PubMedCrossRef
36.
Tierney MC, Szalai JP, Snow WG, Fisher RH, Tsuda T, Chi H, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology. 1996;46:149–54.PubMedCrossRef
37.
Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol. 2000;57:675–80.PubMedCrossRef
38.
Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology. 2001;56:37–42.PubMedCrossRef
39.
Benton A, Hamsher K. Multilingual aphasia examination manual. Iowa City: University of Iowa; 1978.
40.
41.
Kokmen E, Naessens JM, Offord KP. A short test of mental status: description and preliminary results. Mayo Clin Proc. 1987;62:281–8.PubMed
42.
Tang-Wai DF, Knopman DS, Geda YE, Edland SD, Smith GE, Ivnik RJ, et al. Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. Arch Neurol. 2003;60:1777–81.PubMedCrossRef
43.
Ferrarini L, Frisoni GB, Pievani M, Reiber JH, Ganzola R, Milles J. Morphological hippocampal markers for automated detection of Alzheimer's disease and mild cognitive impairment converters in magnetic resonance images. J Alzheimers Dis. 2009;17:643–59.PubMed
44.
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.PubMedCrossRef
45.
Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446–52.PubMedCrossRef
46.
Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2856–66.PubMedCrossRef
47.
Klunk WE, Mathis CA, Price JC, Lopresti BJ, DeKosky ST. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2805–7.PubMedCrossRef
48.
Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66:1469–75.PubMedCrossRef
49.
Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov. 2003;2:646–53.PubMedCrossRef
50.
Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine study group. JAMA. 1994;271:985–91.PubMedCrossRef
51.
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil study group. Neurology. 1998;50:136–45.PubMedCrossRef
52.
Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318:633–8.PubMedCrossRef
53.
Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 study group. BMJ. 2000;321:1445–9.PubMedCrossRef
54.
Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004;161:532–8.PubMedCrossRef
55.
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333–41.PubMedCrossRef
56.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317–24.PubMedCrossRef
57.
Lockhart BP, Lestage PJ. Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which? Exp Gerontol. 2003;38:119–28.PubMedCrossRef
58.
Hayes TL, Larimer N, Adami A, Kaye JA. Medication adherence in healthy elders: small cognitive changes make a big difference. J Aging Health. 2009;21:567–80.PubMedCrossRef
59.
Lloret A, Badia MC, Mora NJ, Pallardo FV, Alonso MD, Vina J. Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis. 2009;17:143–9.PubMed
60.
Miller 3rd ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.PubMed
61.
Geda YE, Petersen RC. Clinical trials in mild cognitive impairment. In: Gauthier S, Cummings J (eds). Alzheimer's disease and related disorders. 2nd edn. Martin Dunitz, London; 2001.
62.
Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004;63:651–7.PubMedCrossRef
63.
Diniz BS, Pinto Jr JA, Gonzaga ML, Guimaraes FM, Gattaz WF, Forlenza OV. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2009;259:248–56.PubMedCrossRef
Metadaten
Titel
Mild Cognitive Impairment in Older Adults
verfasst von
Yonas E. Geda
Publikationsdatum
01.08.2012
Verlag
Current Science Inc.
Erschienen in
Current Psychiatry Reports / Ausgabe 4/2012
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-012-0291-x

Weitere Artikel der Ausgabe 4/2012

Current Psychiatry Reports 4/2012 Zur Ausgabe

Psychiatry in Primary Care (BN Gaynes, Section Editor)

The Depression Treatment Cascade in Primary Care: A Public Health Perspective

Psychiatry in Primary Care (BN Gaynes, Section Editor)

Does Screening for Depression in Primary Care Improve Outcome?

Psychiatry in Primary Care (BN Gaynes, Section Editor)

Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting

Psychiatry in Primary Care (BN Gaynes, Section Editor)

Feasible Evidence-Based Strategies to Manage Depression in Primary Care

Geriatric Disorders (DC Steffens, Section Editor)

Alcohol and Substance Misuse in Older Adults

Invited Commentary

Eating Disorders: Some New Answers to Old Questions

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise